Introduction {#s1}
============

Genes encoding small proteins are not well-characterized in the genomes of bacteria. An examination of the sequenced genomes shows that these small genes are not consistently annotated across related genomes, which raises the question of whether they encode functional genes. Further, the small size of the coding genes reduces the probability of identifying their functions in transposon mutagenesis screens. In bacteria, relatively few small proteins have been characterized. These include the toxin peptides of toxin/antitoxin systems, which insert into membranes and cause damage (Gerdes et al., [@B13]), and peptides that functions as "connectors" of two-component signal transduction systems (Eguchi et al., [@B8]). Recent studies in *Escherichia coli* and *Salmonella enterica* serovar Typhimurium have identified several small proteins whose expression had previously been overlooked in proteomic and genomic studies (Alix and Blanc-Potard, [@B2]; Hemm et al., [@B18]). One of these proteins, MgtR, modulates degradation of MgtC, a cytoplasmic protein involved in replication of *S. typhimurium* within host cells, by the FtsH protease, suggesting a role for MgtR in adaptation to the host environment (Alix and Blanc-Potard, [@B3]). A second peptide found to target the activity of FtsH protease, SpoVM, has been identified in *Bacillus subtilis* (Cutting et al., [@B4]). In *Agrobacterium tumefaciens*, a close phylogenetic relative of the *Brucella* species, a small protein VirE1 has been shown to serve as a secretion chaperone for the Type IV-exported single-strand binding protein VirE2 (Deng et al., [@B6]). Given their potential role in virulence-associated functions, we determined the role in intracellular survival of 30 genes with the potential to encode proteins of \<15 kDa in the intracellular pathogen *Brucella abortus*. One of the proteins identified in this screen, BAB2_0726, was encoded in the 3′ region of *cydAB*, encoding cytochrome *bd* oxidase. This terminal oxidase of the respiratory chain is expressed by *B. suis* inside macrophages, the preferred intracellular niche *in vivo* (Loisel-Meyer et al., [@B29]), and contributes to intracellular replication of *B. abortus*, *B. suis*, and *B. melitensis* (Endley et al., [@B10]; Loisel-Meyer et al., [@B29]; Wu et al., [@B41]). We, therefore, focused our efforts on the contribution of BAB2_0726 to the function of cytochrome *bd* oxidase.

Materials and methods {#s2}
=====================

Bacterial strains, media, and culture conditions
------------------------------------------------

*Escherichia coli* TOP10 cells were used for all cloning steps and transformation of PCR products cloned into the pCR2.1 TOPO vector (Invitrogen). All *E. coli* strains were grown in Luria-Bertani (LB) broth. Antibiotics carbenicillin (Carb) 100 μg/ml, kanamycin (Kan), 100 μg/ml or chloramphenicol (Cm), 30 μg/ml were used as appropriate. *Brucella abortus* biovar 1 strain 2308, a virulent strain originally isolated from cattle, was used for generation of mutants. Bacterial inocula used for infection of mice were cultured on tryptic soy agar (TSA) plus 5% defibrinated sheep blood. The antibiotics Carb 100 μg/ml, Kan, 50 μg/ml; Cm, 15 μg/ml were added as needed. All work with live *B. abortus* was performed at biosafety level 3. Bacterial strains and plasmids used in this study are listed in Table [1](#T1){ref-type="table"}.

###### 

**Strains and plasmids used in this work**.

  **Strain or plasmid**   **Description**                                                                           **Reference or source**
  ----------------------- ----------------------------------------------------------------------------------------- ----------------------------
  **PLASMIDS**                                                                                                      
  pCR2.1                  PCR TOPO cloning vector                                                                   Invitrogen
  pUC4Kixx                1.3 Kb Kan cassette as *Sma*I fragment, Amp^R^, Kan^R^                                    Pharmarcia
  pBBR1MCS4               Broad-host range vector confers Amp^R^                                                    Kovach et al., [@B23]
  pFlagTEM1               Cloning vector to express flagged TEM1 (FT) fusion under control of trc promoter, Cm^R^   Raffatellu et al., [@B34]
  pCydX/FT                Expresses CydX::FT from trc promoter, Cm^R^                                               This study
  pFT/CydX                Expresses FT::CydX from trc promoter, Cm^R^                                               This study
  pGST/FT                 Expresses GST::FT from trc promoter, Cm^R^                                                Raffatellu et al., [@B34]
  pFT/GST                 Expresses FT::GST fromtrc promoter, Cm^R^                                                 de Jong et al., [@B21]
  pGroEL/dsRed            Expresses DsRed from *Brucella* GroEL promoter, Cm^R^                                     This study
  pGroEL/CydX             Expresses CydX from *Brucella* GroEL promoter, Cm^R^                                      This study
  pGroEL/CydB             Expresses CydB from *Brucella* GroEL promoter, Cm^R^                                      This study
  pGroEL/CydBX            Expresses CydBX from *Brucella* GroEL promoter, Cm^R^                                     This study
  pBBR1Flag               Cloning vector to express flagged fusion under *Brucella* constitutive promoter, Cm^R^    This study
  pCydX/Flag              Expresses CydX::Flag from *Brucella* constitutive promoter, Cm^R^                         This study
  **BRUCELLA**                                                                                                      
  *B. abortus* 2308       Wild type                                                                                 
  ADH3                    Δ*vir*B2 (non polar) in *B. abortus* 2308                                                 den Hartigh et al., [@B17]
  BA41                    Δ*vir*B1::Tn5 in *B. abortus* 2308                                                        Hong et al., [@B19]
  BA582                   Δ*cyd*B::Tn5 in *B. abortus* 2308                                                         Endley et al., [@B10]
                          ΔBAB1_0061::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB1_0355::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB1_0513::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB1_0581::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB1_0626::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB1_0743::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB1_0992::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB1_1106::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB1_1194::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB1_1204::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB1_1262::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB1_1390::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB1_1392::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB1_1743::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB1_1748::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB1_1939::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB1_2041::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB2_0160::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB2_0170::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB2_0862::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB2_0761::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB2_0726::Kan in *B. abortus* 2308 (Δ*cyd*X::Kan)                                       This study
                          ΔBAB2_0470::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB2_0450::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB2_0415::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB2_0400::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB2_0232::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB2_1072::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB2_1087::Kan in *B. abortus* 2308                                                      This study
                          ΔBAB2_1036::Kan in *B. abortus* 2308                                                      This study
                          *B. abortus* 2308 with pCydX/Flag                                                         This study
                          *B. abortus* 2308 with pBBR1MCS4                                                          This study
                          *B. abortus* 2308 with pFlagTEM1                                                          de Jong et al., [@B21]
                          *B. abortus* 2308 with pCydX/FT                                                           This study
                          *B. abortus* 2308 with pFT/CydX                                                           This study
                          *B. abortus* 2308 with pGST/FT                                                            This study
                          *B. abortus* 2308 with pFT/GST                                                            de Jong et al., [@B21]
                          Δ*cyd*X::Kan with pGroEL/dsRed                                                            This study
                          Δ*cyd*X::Kan with pGroEL/CydX                                                             This study
                          Δ*cyd*X::Kan with pCydX/Flag                                                              This study
                          BA582 with pGroEL/CydX                                                                    This study
                          BA582 with pGroEL/CydB                                                                    This study
                          BA582 with pGroEL/CydBX                                                                   This study

Allelic exchange mutagenesis
----------------------------

A previously reported three-step cloning strategy (Sun et al., [@B37]) was used to construct mutants for small open reading frames (Figure [A1](#FA1){ref-type="fig"}). Briefly, an upstream fragment (with a *Sma*I site in reverse primer) and a downstream fragment (with a *Sma*I site in forward primer and a *Pst*I site in reverse primer), both measuring about 600--1200 bp, were amplified and cloned in pCR2.1. The orientation of the upstream fragment was determined by PCR using one primer specific for the insert and one primer specific for the vector (for example T7 promoter primer) to identify a clone with the *Sma*I site located at the f1 origin end of the multiple cloning site in TOPO cloning vector pCR2.1. The *Sma*I/*Pst*I digested downstream fragment was then cloned next to the upstream fragment by using ampicillin for selection marker since the *Sma*I/*Pst*I double digestion of vector cleaves a 1.2 Kb fragment from pCR2.1 backbone including part of kanamycin resistance gene. A 1.3 Kb *Sma*I fragment of pUC4KIXX (Pharmacia) containing the Tn*5* kanamycin resistance gene was then cloned into the *Sma*I site to generate a construct for the allelic exchange of candidate gene with a deleted copy replaced by a kanamycin resistance gene. These plasmids were introduced into *B. abortus* 2308 by electroporation. Recombinants were screened for kanamycin resistance and carbenicillin sensitivity. Deletion of target genes was confirmed by PCR or/and southern blot.

RNA preparation and RT-PCR
--------------------------

*B. abortus* strains were grown for 48 h in tryptic soy broth (TSB) in parafilm-sealed tubes with minimal headspace to limit oxygen availability. The cells were harvested by centrifugation at 5000 × *g*. Total RNA was isolated using the Aurum Mini Kit (Bio-rad). RNA samples were digested with RNase-free DNase I (Invitrogen) and quantified using a NanoDrop spectrophometer (Thermo Scientific) at 260/280 nm. Reverse transcription was carried out using a standard protocol and MMLV Reverse Transcriptase (Invitrogen). Primer pairs used to amplify *cydA* (247 bp), *cydB* (243 bp), and *cydX* (204 bp) are listed in Table [A1](#TA1){ref-type="table"}. PCR primers (2 μM) and cDNAs were added in PCR SuperMix (Invitrogen), and heated to 95°C for 5 min. Reactions omitting the reverse transcriptase served as negative controls. The PCR cycle consisted of 94°C for 10 s (denaturation), 52--55°C for 30 s (annealing), and 72°C for 10 s (extension), and this was repeated 30 times. PCR products were visualized after agarose gel (1.4%) electrophoresis and SYBR staining (Invitrogen).

Macrophage killing assay
------------------------

The mouse macrophage-like cell line J774A.1, obtained from ATCC, was cultured in Dulbecco\'s Modified Eagle\'s Medium (DMEM; Gibco, Rockville, MD) supplemented with 10% heat-inactivated fetal bovine serum, 1% non-essential amino acids, and 1 mM Glutamine (DMEMsup). For macrophage killing assays, 24-well microtiter dishes were seeded with macrophages at a concentration of 1--2 × 105 cells/well in 0.5 ml of DMEMsup and incubated over night at 37°C in 5% CO~2~. Inocula were prepared by growth with shaking in TSB for 24 h, then subsequent dilution in DMEMsup to a concentration of 4 × 10^7^ colony-forming units (CFU)/ml. Approximately 2 × 10^7^ bacteria in 0.5 ml of DMEMsup, containing single or a 1:1 mixture of wild type and mutant, were added to each well of macrophages. Microtiter dishes were centrifuged at 250 × *g* for 5 min at room temperature in order to synchronize infection. Cells were incubated for 20 min at 37°C in 5% CO~2~, free bacteria were removed by three washes with phosphate-buffered saline (PBS). DMEMsup plus 50 μg gentamicin per ml was added to the wells, and the cells were incubated at 37°C in 5% CO~2~. After 1 h, the DMEMsup plus 50 μg/ml gentamicin was replaced with medium containing 25 μg/ml gentamicin. Wells were sampled at 48 h after infection by aspirating the medium, lysing the macrophages with 0.5 ml of 0.5% Tween-20 and rinsing each well with 0.5 ml of PBS. Viable bacteria were quantified by dilution in sterile PBS and plating on TSA or/and TSA + Kan. Competitive Index, which were adjusted by inocula CFU, were calculated as Mutant CFU/WT CFU per well.

Competitive infection in mice
-----------------------------

Female BALB/c ByJ mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and used at an age of 6--10 weeks. For mixed infection experiments, groups of 2--5 mice were inoculated intraperitoneally with 0.5 ml of PBS containing 2 × 10^5^ CFU of a 1:1 mixture of *B. abortus* wild type and the isogenic mutant. Infected mice were held in microisolator cages in a Biosafety Level 3 facility. At four weeks post-infection, mice were euthanized by CO~2~ asphyxiation and the spleens were collected aseptically at necropsy. Spleens were homogenized in 3 ml of PBS and serial dilutions of the homogenate plated on TSA and TSA containing kanamycin, for enumeration of mutant and wild type CFU. Competitive Index was calculated as Mutant CFU/WT CFU recovered from the spleen divided by Mutant CFU/WT CFU in the inoculum. Animal experiments were approved by the UC Davis Institutional Animal Care and Use Committee.

Assay for loss of stationary phase viability
--------------------------------------------

*B. abortus* cells, freshly re-suspended from TSA plates, were washed once with PBS and diluted into 5 ml TSB or modified minimal E-medium (Kulakov et al., [@B24]) pH 7.0 with starting OD~600~ = 0.01. Bacteria were grown in a shaking incubator at optimal condition of 200 rpm, 37°C, and 5% CO~2~. At time points up to seven days bacterial CFU were enumerated by serial dilution and plating on TSA. Loss of viability during stationary phase was defined as a reduction in bacterial numbers after 72 h incubation. Experiments were repeated at least three times and produced similar results. Results of a representative experiment are shown.

Acid tolerance test
-------------------

After 24 h of growth in E-medium pH 7.0, bacteria were washed once with PBS and re-suspended in the same volume of E-medium adjusted to pH 7.0, or to pH 5.0 or 3.5 with 1 M Citric Acid. After 5 h incubation, CFU were determined by serial diluting and plating on TSA. Acid tolerance was measured by comparing growth at pH 3.5 or 5.0 to growth at pH 7.0. Experiments were repeated at least three times and produced similar results, and representative results are shown.

Sensitivity to nickel sulfate and sodium azide
----------------------------------------------

To test *Brucella* sensitivity to heavy metal and respiratory chain inhibitor, a previously described method was used with modification (Endley et al., [@B10]). Log phase bacteria, obtained after 24 h growth in E-medium pH 7.0, were serially diluted and plated on TSA or TSA supplemented with 0.15 mM NiSO~4~ and 0.15 mM NaN~3~. CFU were counted after five days\' incubation. Experiments were repeated at least three times, with similar results. Data from a representative experiment are shown.

Measurement of hydrogen peroxide sensitivity
--------------------------------------------

To measure hydrogen peroxide sensitivity, a previously described method was used (Elzer et al., [@B9]). Briefly, bacteria lawns from exponential growth phase were made by plating 100 μl *Brucella* growing in E-medium pH 7.0 on TSA plates. A small sterile disk of Whatman paper containing 5 μl 30% H~2~O~2~ was placed in the middle of each lawn. After five days\' incubation, the zone of bacterial clearance was measured. Experiments were repeated at least three times with triplicate plates. Results from a single representative experiment are shown.

Complementation of the *cydX* mutant
------------------------------------

In order to restore a functional copy of *cydX* in the mutant, a previously described *groEL* promoter (Gor and Mayfield, [@B14]; Lin et al., [@B27]) corresponding to *Brucella abortus* 2308 chromosome II DNA coordinates 184149--184551 with engineered restriction enzyme sites was amplified using primers GroEL-P-F and GroEL-P-R and cloned into the pCR2.1 TOPO cloning vector. The insert was excised using *Sph*I and *Nde*I and ligated into broad host range cloning vector pFlagTEM1 (GeneBank accession number EU44730) (Raffatellu et al., [@B34]; Sun et al., [@B38]) to replace lacI^*q*^ and the *trc* promoter. *cydX*, *cydB*, and *cydBX* were amplified from *Brucella abortus* 2308 genomic DNA, respectively, cloned into TOPO vector and then introduced just downstream of the *groEL* promoter using *Nde*I and *Pst*I, to generate plasmids pGroEL/CydX, pGroEL/CydB, and pGroEL/CydBX. To show functionality of the GroEL promoter in *B. abortus*, a DsRed gene, encoding a red fluorescent protein (Shaner et al., [@B36]), was also cloned in the same way to generate pGroEL/dsRed. In order to monitor CydX expression, a plasmid with a 3×FLAG tag fused at the C terminus of CydX was constructed so that CydX expression as a tagged protein could be conveniently detected by using anti-FLAG monoclonal antibody (Sigma). Briefly, to ensure 3×FLAG---tagged protein expression in *Brucella*, a promoter demonstrated previously to be constitutively active under *in vitro* growth conditions (Eskra et al., [@B11]), corresponding to *B. abortus* 2308 chromosome II DNA coordinates 1045014 and 1045238 was amplified with primers Promoter-F and Promoter-R. The 226 bp amplicon flanked by *Kpn*I-*Hpa*I and *Nde*I-*Sal*I was cloned into pCR2.1 TOPO vector and the orientation was chosen in such a way that double digestion with *Sal*I/*Sac*I did not excise the insert. 3×FLAG with two stop codons, amplified from pSUB11 (Uzzau et al., [@B39]) using primer pair of Flag-F and Flag-R, digested with *Sal*I and *Sac*I, was then ligated with constitutive promoter P~BMEII0192~ in pCR2.1 TOPO vector. The 270 bp of "P~BMEII0192~-*Nde*I-*Sal*I-3×FLAG," digested as *Kpn*I/*Sac*I fragment, was inserted into the same sites of pBBR1MCS (Elzer et al., [@B9]) to give rise to pBBR1Flag. Plasmid pCydX/Flag was made by cloning *cydX*, which was amplified from the *B. abortus* genome, TOPO-cloned into pCR2.1, and excised as *Nde*I/*Xho*I fragment, into *Nde*I/*Sal*I sites of pFlag (*Xho*I and *Sal*I sites are compatible). All constructs were confirmed by DNA sequencing to ensure correct insertion and/or in frame expression of fusion proteins. All primers were used in this work are listed in Table [A1](#TA1){ref-type="table"}.

Determining CydX localization and orientation using β-lactamase as a reporter
-----------------------------------------------------------------------------

pFlagTEM1 (Raffatellu et al., [@B34]; Sun et al., [@B38]) was used to express β-lactamase fusions to CydX. To express 3×FLAG-tagged β-lactamase as an fusion to the C-terminus of CydX (CydX::TEM1) *cydX* from *B. abortus* 2308 was amplified without STOP codon, inserted into pCR2.1 and excised as an *Nde*I and *Sal*I fragment. This fragment was then cloned into plasmid pFlagTEM1 using *Nde*I and *Xho*I. Similarly, to fuse 3×FLAG-tagged β-lactamase to the N terminus of CydX, *cyd*X was amplified and cloned into pFlagTEM1 using *Xba*I and *Pst*I to express TEM1::CydX. Other fusions were made in the same way or have been already described (Table [1](#T1){ref-type="table"}). All constructs were sequenced to ensure in frame expression as Flag tagged TEM-1 fusion proteins.

Fresh bacteria growing on plates were resuspended in TSB. Serial dilutions were made after OD~600~ was measured. 10 μl of bacteria containing about 10^3^ CFU were spotted on TSA in 96-well plates with 100 μg/ml Carb, or 1 mM IPTG plus 15 μg/ml Cm, or IPTG plus Carb which concentrations range from 0 to 1 mg/ml. Plates were checked after five days\' incubation to determine bacterial viability. Survival was scored as the maximum antibiotic concentration permitting growth of *B. abortus*.

SDS-page and western blotting
-----------------------------

To measure expression of 3×FLAG-tagged or/and β-lactamase fusion proteins, *B. abortus* was cultured in TSB at 37°C with shaking at 200 rpm. After 18 h the OD~600~ of the cultures ranged from 1.2 to 1.5 and bacteria were pelleted and resuspended in 1X Laemmli sample buffer, heated at 100°C for 5 min, and the total protein equivalent to 1 × 10^8^ CFU loaded per well was then electrophoresed on a 12--15% polyacrylamide gel and transferred to nitrocellulose membrane. Membranes were blocked in 2% non-fat skim milk in PBS for an hour and then probed with Anti-FLAG Monoclonal antibody (1:5000, Sigma) or anti-β-lactamase monoclonal antibody (1:5000, QED Bioscience Inc.). Primary antibody binding was detected using a goat-anti-mouse antibody conjugated to horseradish peroxidase (HRP). HRP activity was detected with a chemiluminescent substrate (NEN). A previously described polyclonal antibody against the *B. abortus* protein Bcsp31 was used as a loading control (Sun et al., [@B37]).

Results and discussion {#s3}
======================

Targeted mutagenesis of small hypothetical ORFs
-----------------------------------------------

Using the published genome sequences of *B. abortus* 2308, *B. suis* 1330, and *B. melitensis* 16 M, we identified ORFs with the potential to encode proteins smaller than 15 kDa. Thirty of these ORFS were selected for mutagenesis based on having no predicted function and lack of annotation in the genome of *A. tumefaciens* C58. Some of these proteins were assigned families of conserved proteins such as clusters of orthologous genes (COG) with only general functional predictions or families containing conserved domains of unknown function (DUF). Precise deletions of each ORF were constructed and marked with a kanamycin resistance gene (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). Mutations were confirmed by PCR, and/or by Southern blot using probes specific to the deleted gene. For 30 genes we could confirm inactivation (See Figure [A1](#FA1){ref-type="fig"} for details of the mutagenesis procedure).

###### 

**Small ORFs (\<15 kDa) with no assigned function, which are highly conserved in *Brucella* species**.

  ***B. abortus* 2308 ORF[^*a*^](#TN1){ref-type="table-fn"}**   ***B. suis* 1330 ORF[^*a*^](#TN1){ref-type="table-fn"}**   ***B. melitensis* 16M ORF[^*a*^](#TN1){ref-type="table-fn"}**   **Annotation[^*b*^](#TN2){ref-type="table-fn"}**                                            ***In vitro* CI[^*c*^](#TN3){ref-type="table-fn"}**   ***In vivo* CI[^*d*^](#TN4){ref-type="table-fn"}**
  ------------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------
  BAB2_0068[^*e*^](#TN5){ref-type="table-fn"}                   BRA0069                                                    BMEII0025                                                       Type IV secretion system protein virB1                                                      0.0023                                                0.0001
  BAB1_0061                                                     BR0064                                                     BMEI1881                                                        hypothetical protein                                                                        0.7493                                                1.2039
  BAB1_0355                                                     BR0325                                                     BMEI1597                                                        COG1380 LrgA family protein \[general function prediction only\]                            1.3655                                                0.0153
  BAB1_0513                                                     BR0488                                                     BMEI1447                                                        hypothetical protein                                                                        5.6537                                                1.0448
  BAB1_0581                                                     BR0557                                                     BMEI1376                                                        COG3654; prophage maintenance system killer protein \[general function prediction only\]    1.8387                                                0.5577
  BAB1_0626                                                     BR0602                                                     BMEI1339                                                        hypothetical protein                                                                        3.6877                                                N
  BAB1_0743                                                     BR0725                                                     BMEI1227                                                        hypothetical protein \[possible relationship to acetyltransferases\]                        0.6340                                                0.6160
  BAB1_0992                                                     BR0973                                                     BMEI1005                                                        hypothetical protein                                                                        1.1191                                                0.4853
  BAB1_1106                                                     BR1083                                                     BMEI0899                                                        COG3617; prophage antirepressor \[possible function in transcription\]                      1.2815                                                0.6963
  BAB1_1194                                                     BR1173                                                     BMEI0813                                                        hypothetical protein                                                                        1.2322                                                0.3799
  BAB1_1204                                                     BR1181                                                     BMEI0806                                                        hypothetical protein                                                                        1.3258                                                0.4248
  BAB1_1262                                                     BR1241                                                     BMEI0751                                                        hypothetical protein                                                                        N                                                     1.5608
  BAB1_1390                                                     BR1370                                                     BMEI0633                                                        COG0239; possible integral membrane protein                                                 N                                                     1.8630
  BAB1_1392                                                     BR1372                                                     BMEI0631                                                        COG3467; predicted flavin nucleotide binding protein \[general function prediction only\]   N                                                     1.4038
  BAB1_1743                                                     BR1730                                                     BMEI0308                                                        hypothetical protein                                                                        0.6744                                                N
  BAB1_1748                                                     BR1736                                                     BMEI0304                                                        COG1607, Acyl-CoA hydrolase \[Lipid metabolism\]                                            N                                                     1.3140
  BAB1_1939                                                     BR1938                                                     BMEI0127                                                        hypothetical protein                                                                        0.4634                                                0.4569
  BAB1_2041                                                     BR2041                                                     BMEI0030                                                        DUF188 superfamily                                                                          2.6421                                                0.5280
  BAB2_0160                                                     BRA0162                                                    BMEII1078                                                       COG4893; uncharacterized protein conserved in bacteria                                      0.6152                                                1.1670
  BAB2_0170                                                     BRA0175                                                    BMEII1067                                                       DUF465 superfamily; putative cytosolic protein                                              0.2584                                                N
  BAB2_0761                                                     BRA0476                                                    BMEII0789                                                       hypothetical protein                                                                        0.5177                                                N
  BAB2_0726                                                     BRA0512                                                    BMEII0758                                                       Pfam01873; YbgT-like protein                                                                0.0079                                                0.0001
  BAB2_0470                                                     BRA0769                                                    BMEII0522                                                       Pfam05635; family of hypothetical proteins                                                  0.0002                                                0.0025
  BAB2_0450                                                     BRA0787                                                    BMEII0503                                                       hypothetical protein                                                                        0.0435                                                0.0180
  BAB2_0415                                                     BRA0819                                                    BMEII0468                                                       hypothetical protein                                                                        1.0595                                                1.2254
  BAB2_0400                                                     BRA0836                                                    BMEII0454                                                       hypothetical protein                                                                        1.0501                                                1.8400
  BAB2_0232                                                     BRA1000                                                    BMEII0296                                                       hypothetical protein                                                                        N                                                     0.9205
  BAB2_1072                                                     BRA1113                                                    BMEII0186                                                       pemK family protein \[possible regulator\]                                                  5.1792                                                0.5605
  BAB2_1087                                                     BRA1130                                                    BMEII0169                                                       Hypothetical protein \[flagellar locus\]                                                    N                                                     1.0841
  BAB2_1136                                                     BRA1177                                                    BMEII0118                                                       DUF1634 superfamily                                                                         0.2300                                                0.4828

ORF number from NCBI.

Followed B. suis 1330 assignment.

Competitive index (CI): Calculated as Mean Mutants/WT from at least three experiments. N: Not tested.

Competitive index (CI): Calculated as Mean Mutants/WT in spleen of 2--5 mice. N: Not tested.

A previously characterized virB1 mutant (BA41) serves as attenuation phenotype control.

Mutants BAB2_0726, BAB2_0470, and BAB2_0450 are highly attenuated both in cultured macrophages *in vitro* and in a mouse model *in vivo.*
-----------------------------------------------------------------------------------------------------------------------------------------

In order to determine whether any of the genes inactivated in the collection of mutants were required for intracellular survival we tested the ability of 30 mutants to survive and replicate for 48 h within cells of the macrophage-like line J774. All the mutants had similar growth rates as wild type *B. abortus* when growing in TSB (data not shown). Three mutants, BAB2_0726, BAB2_0470, and BAB2_0450 exhibited marked intracellular growth defects in a competitive infection against wild type in J774 macrophage-like cells (Table [2](#T2){ref-type="table"}). Macrophage infection experiments were repeated with individual mutants (non-competitive infection) and exhibited the same attenuation phenotype as in mixed infection. After 48 h infection, the intracellular CFU of mutants BAB2_0726, BAB2_0470, and BAB2_0450 was decreased 2--3 orders of magnitude compared with wild type although they were less attenuated than ADH3 (*virB2*), a mutant defective in the type IV secretion system (den Hartigh et al., [@B17]) (Table [2](#T2){ref-type="table"}).

We also investigated the role of these small hypothetical genes in persistent infection in a mouse model. To minimize the variation caused by different inoculum doses, we conducted competitive infection experiments, in which we inoculated mice IP with a 1:1 mixture of each mutant with wild type *B. abortus* 2308. Four weeks after inoculation, bacterial load in spleens were determined by differential plating on TSA with or without kanamycin and the competitive index was calculated as CFU of mutants/CFU of wild type and corrected for mutant/wild type ratio in each inoculum. Most of the mutants were recovered in a number similar to the wild type from the spleen of infected mice, suggesting that these mutants have equal ability to persist for up to four weeks. However, three mutants were attenuated compared with wild type, having competitive indices ranging from 0.018 to 0.001. Consistent with the attenuation phenotype observed in cultured mouse macrophages *in vitro*, mutants BAB2_0726, BAB2_0470, and BAB2_0450 were highly attenuated *in vivo* (Table [2](#T2){ref-type="table"}). A fourth mutant, BAB1_0355, was found to be attenuated in the *in vivo* competitive infection assay, but not in J774 cells (Table [2](#T2){ref-type="table"}). BAB1_0355 is related to LrgA of *Staphylococcus aureus*, which encodes a regulator of murein hydrolase (Groicher et al., [@B16]). BAB2_0450 is upstream of a predicted carbonic anhydrase, which has been characterized as a target for anti-*Brucella* drugs (Joseph et al., [@B22]), so its function may be related to that of the carbonic anhydrase, or its deletion may have a polar effect on carbonic anyhdrase expression. BAB2_0470 belongs to a family of proteins designated "S23 ribosomal proteins" which share similarity to proteins of unknown function encoded by an intervening sequence in the 23S ribosomal genes of *Leptospira* and *Coxiella burnetii* (Ralph and McClelland, [@B35]; Afseth et al., [@B1]).

BAB2_0726 is located in the 3′ end of *cyd* operon and the phenotype of a deletion mutant is similar to that of *cydB* mutants
------------------------------------------------------------------------------------------------------------------------------

The *in vitro* and *in vivo* attenuation phenotypes of mutants BAB2_0726, BAB2_0470, and BAB2_0450 raised the question of how these small hypothetical proteins could contribute to *Brucella* virulence. While analysis of BAB2_0470 and BAB2_0450 did not reveal any clues to their function, by looking the gene organization of BAB2_0726 in *Brucella abortus* 2308 genome we found that BAB2_0726 is located at the 3′ end of the *cydAB* operon, a gene cluster encoding subunits of a high affinity terminal oxidase of the oxygen respiratory chain (Endley et al., [@B10]) (Figure [1A](#F1){ref-type="fig"}). This gene organization pattern is well conserved in all sequenced *Brucella* genomes. The localization of a small peptide downstream of *cydB* was also reported in *Escherichia coli*, where it has been designated *orfC* or *ybgT* (Muller and Webster, [@B32]; Hemm et al., [@B18]). This finding led us to designate BAB2_0726 as *cydX*, since *cydC* (*BAB2_0729*) and *cydD* (*BAB2_0730*) immediately upstream of *cydA* were already assigned in *E. coli* to genes encoding a bacterial glutathione transporter (Pittman et al., [@B33]).

![***cydA, cydB, and cydX* are organized and transcribed as a gene cluster. (A)** Genetic map of the *cyd* locus in *B. abortus* 2308 chromosome II. *cydA* and *cydB* encode two proteins with similarity to subunit I and II of cytochrome *bd*-1 terminal oxidase in *E. coli.* Upstream of *cydA* and *cydB* are two predicted ABC transporter genes with similarity to *E. colicydD* and *cydC*. Overlapping 23 bp with *cydB*, *cydX* encodes a 64 aa protein with one predicted transmembrane domain (shaded), spanning residues 17--35. While no promoter is predicted in front of *cydD* there is a promoter (P~cydAB~), possibly driving transcription of *cydA*, *cydB*, and *cyd*X. A transcriptional terminator (circled T) is located between *cydX* and its adjacent open reading frame BAB2_0725. In BA582 (*cydB*::Tn*5*) a transposon is inserted in *cydB* (triangle) while in *cydX*::Kan part of *cydX* (hatched) is replaced by a kanamycin resistance determinant without disrupting *cydB*. **(B)** Analysis of the *cyd* gene cluster by RT-PCR. PCR products for the indicated primers with wild type *(WT) or cydB*::Tn5 *mutant* (BA582) as a template are shown. The sizes of the predicted amplicons for *cydA*, *cydB*, and *cydX* are 247 bp, 243 bp, and 204 bp, respectively. Control reactions in which reverse transcriptase were omitted had no amplification product (not shown).](fcimb-02-00047-g0001){#F1}

Since based on *in silico* analysis, *cydA*, *cydB*, and *cydX* are predicted to be transcribed together from a promoter upstream of *cydA*, we determined whether insertional activation of *cydB* would be polar on *cydX* expression (Figure [1B](#F1){ref-type="fig"}). To this end, RT-PCR was performed to assay expression of *cydA*, *cydB*, and *cydX* in *B. abortus* 2308 (WT) or an isogenic Tn*5* insertion in *cydB* (Endley et al., [@B10]). While a faint product for *cydA* was observed in both WT and the *cydB* mutant, neither *cydB* nor *cydX* amplification products were found in the *cydB* mutant, suggesting a polar effect of the *cydB* mutation on *cydX* expression. These results suggested that *cydX* is transcribed together with the cytochrome *bd* oxidase subunits encoded by *cydA* and *cydB*.

To determine whether CydX is functionally related to cytochrome *bd* oxidase, we determined whether deletion of *cydX* affects stationary phase viability, a phenotype that is defective in a *B. abortus cydB* mutant (Endley et al., [@B10]). As shown in Figure [2A](#F2){ref-type="fig"}, when grown in minimum medium with starting OD~600~ = 0.05 all *Brucella* strains replicated equally until they reached stationary phase (48--72 h). However, similar to the *cydB* mutant BA582, the viability of the mutant deleted for *cydX* declined rapidly as the incubation time progressed, while wild type *B. abortus* survived for up to five days. Similar results were observed when the mutants were grown in rich medium (TSB) (data not shown). Our finding that deletion of *cydX* impaired intracellular growth (Table [2](#T2){ref-type="table"}) and led to loss of viability in stationary phase (Figure [2A](#F2){ref-type="fig"}) prompted us to determine whether this mutant shared other defects associated with inactivation of cytochrome *bd* oxidase (Endley et al., [@B10]). Similar to a *cydB* mutant, the *B. abortus* mutant lacking *cydX* exhibited significantly (*P* \< 0.01) increased sensitivity to hydrogen peroxide compared with wild type *B. abortus* (Figures [2C,D](#F2){ref-type="fig"}).

![**Characterization of the *cyd*X mutant. (A)** Loss of viability in stationary phase. Growth kinetics of *B. abortus* in modified E medium pH 7.0 was monitored by CFU counting at each indicated time point. Each data point represents results of a single assay that was repeated twice. **(B)** Intracellular survival of the *cydX* mutant in J774 macrophages. Strain ADH3 (*virB2*) served as an attenuated control. Data are represented as the mean ± standard deviation (SD) of triplicate samples from one assay that was repeated twice with the same result. Significance of differences was analyzed by One-Way analysis of variance (ANOVA), with a *P* value of less than 0.05 considered as significant. The dotted line indicates the limit of detection. **(C** and **D)** Sensitivity to hydrogen peroxide. Log-phase bacteria were plated on TSA and oxidative killing was determined by measuring the diameter of clear zone surrounding a paper disk soaked with 5 μl of 30% hydrogen peroxide. Large zones of bacterial growth inhibition were observed in both *cydX* and *cydB* mutants (Typical photographs were shown). Data in **(D)** are represented as means of a single assay with five samples ± SD, that was repeated once with the same result. Significance of differences was analyzed by One-Way ANOVA, with *P* values for pairwise comparisons with *P* \< 0.05 indicated. **(E)** Sensitivity to sodium azide plus nickel sulfate. Log-phase bacteria growing TSA or TSA supplemented with 0.15 mM NiSO~4~ and 0.15 mM NaN~3~ were serially diluted and were plated on TSA for enumeration of surviving bacteria. Survival of treatment with sodium azide plus nickel sulfate was calculated as the ratio of CFU on TSA + NiSO~4~ /NaN~3~ to CFU on TSA. While these ratios were approximately 1 for wild type *B. abortus*, neither *cydX* mutant nor the *cydB* mutant survived in the presence of these chemicals. A dotted line indicates the limit of detection of this assay.](fcimb-02-00047-g0002){#F2}

Disruption of cytochrome *bd* oxidase increases sensitivity to the respiratory chain inhibitor sodium azide and the uncoupling agent nickel in both *Brucella* and *E. coli* (Wall et al., [@B40]; Edwards et al., [@B7]; Endley et al., [@B10]). Similarly to the *B. abortus cydB* mutant, the mutant lacking *cydX* was highly sensitive to the combination of sodium azide plus nickel sulfate, compared to wild type *B. abortus* (Figure [2E](#F2){ref-type="fig"}). The data suggested that the small protein CydX is required for the function of cytochrome *bd* oxidase in *B. abortus*.

Complementation of the *cydX* mutant leads to partial restoration of *cyd* phenotypes and improves intracellular growth in mouse macrophages.
---------------------------------------------------------------------------------------------------------------------------------------------

To confirm that the phenotypes of the *cydX*::Kan mutant result from deletion of *cydX*, we conducted complementation experiments to satisfy the molecular Koch\'s postulates (Falkow, [@B12]). To this end, constructs encoding either CydX or CydX::3 ×-FLAG were generated. The *groEL* promoter, known to be induced during growth in macrophages (Lin and Ficht, [@B28]), was used to drive *cydX* expression. As a control for the expression of *cydX*, we expressed the gene encoding the fluorescent protein DsRed from the same promoter and confirmed fluorescence of the recombinant strain (not shown). Immunoblot analysis of *Brucella* expressing CydX::FLAG with anti-Flag antibody revealed a major band of 10 kDa, a size matching the predicted size of CydX (8 kDa) and 3×FLAG (2 kDa), indicating that CydX is indeed expressed as protein in *Brucella* (not shown). Both the *cydX* mutant and BA582 (*cydB*::Tn*5*) were transformed with constructs expressing *cydX*, *cydB*, or *cydBX* to determine whether the phenotypes associated with cytochrome *bd* oxidase deficiency could be complemented (Figure [3](#F3){ref-type="fig"}). Complementation of both *cydB* and *cydX* mutants with their respective genes restored stationary phase viability (Figure [3A](#F3){ref-type="fig"}), and complementation of this phenotype in the *cydX* mutant was unaffected by addition of the 3X-FLAG tag to the C terminus of CydX. As expected, the construct expressing DsRed failed to complement the *cydX* mutant since it expressed an irrelevant control protein.

![**Complementation of *cydX* mutation.** Plasmid-encoded copies of *cydB* or *cydBX*, *cydXor cydX-FLAG* were introduced into *cydX* and *cydB* mutants. A plasmid expressing DsRed served as a negative control. **(A)** Restoration of stationary phase viability was determined as decribed in Figure [2](#F2){ref-type="fig"}. **(B)** Sensitivity to 3% Hydrogen peroxide was assayed as described in Figure [2](#F2){ref-type="fig"}. Significance of differences was analyzed by One-Way ANOVA, with *P* values for pairwise comparisons with *P* \< 0.05 indicated. **(C)** Sensitivity to sodium azide plus nickel sulfate was assayed as described in Figure [2](#F2){ref-type="fig"}. **(D)** Sensitivity to acid pH. Viability of cultures incubated for 5 h in E-medium adjusted to pH 7.0 or pH 3.5 was assayed as described in the Materials and Methods. Each data point represents results of a single assay that was repeated twice. **(E)** Survival in J774 mouse macrophages. J774 cells were infected with *cydX* or *cydB* mutants containing indicated plasmids. Cells were lysed at 24 and 48 h post-infection. Bacterial CFU were determined by serial dilution and plating on TSA. Data represent the mean of triplicate samples ±SD from a single experiment of three replicates with similar results. Significance of differences was analyzed by One-Way ANOVA, with *P* values for pairwise comparisons with *P* \< 0.05 indicated. Dotted lines indicate the limit of detection.](fcimb-02-00047-g0003){#F3}

Complementation of hydrogen peroxide sensitivity in the *cydX* mutant was also observed with constructs expressing CydX or CydX::Flag, as evidenced by the reduced zone of clearance around filter disks containing hydrogen peroxide (Figure [3B](#F3){ref-type="fig"}). Introduction of a construct encoding *cydBX* into the *cydB* mutant (BA582) resulted in greater resistance to H~2~O~2~ compared to introduction of a construct encoding *cydB* only (Figure [3B](#F3){ref-type="fig"}). This result suggested that the Tn*5* insertion in *cydB* in BA582 could have a polar effect on expression of *cydX*.

A second phenotype of the *cydX* mutant, lack of growth in the presence of nickel and azide, was also complemented to the wild type level by introduction of an intact copy of *cydX* or *cydX::3x-Flag*, similar to what was observed for complementation of the *cydB* mutant (Figure [3C](#F3){ref-type="fig"}).

Two *cydX* mutant phenotypes, sensitivity to acidic conditions and intracellular survival in J774 macrophages, were only partially complemented by introduction of constructs expressing CydX or CydX::FLAG (Figures [3D,E](#F3){ref-type="fig"}). In the experiment shown in Figure [3E](#F3){ref-type="fig"}, there were no remarkable differences between CydX mutant transformed with pGroEL/dsRed, pGroEL/CydX, or pCydX/Flag at 24 h post-infection. However, at 48 h post-infection, the CFU recovered for mutants complemented with CydX or CydX::Flag were markedly higher than that of mutant transformed with pGroEL/dsRed (control). Complementation of the *cydX* mutant with constructs expressing CydX or CydX::FLAG resulted in partial restoration of intracellular survival, with a net increase in bacterial numbers between 24 and 48 h. In contrast, the *cydX* mutant complemented with the DsRed-expressing construct failed to replicate during this time and actually decreased in numbers. Based on this observation we concluded that the intracellular growth defect of *cydX* mutant with impaired cytochrome *bd* oxidase activity could be partially rescued by providing wild type CydX or CydX::FLAG *in trans*. Interestingly, expression of *cydX* together with *cydB* increased survival of the *cydB* mutant more then complementation with *cydB* alone (Figure [3E](#F3){ref-type="fig"}). However, expression of *cydX* alone in the same copy number did not completely restore intracellular replication of the *cydX* mutant.

It was of interest that while some phenotypes of the *cydX* mutant, such as sensitivity to H~2~O~2~ or nickel sulfate/sodium azide, could be complemented to the level of the wild type, survival of pH 3.5 or intracellular replication of the *cydX* mutant were restored to a lesser degree. It is possible that these two former phenotypes require only some degree of cytochrome *bd* oxidase activity, whereas intracellular growth and acid resistance represent stress conditions that may require either precise regulation of *cydABX* expression or specific ratios of CydX to CydA and CydB. Since CydX is predicted to be an integral cytoplasmic protein (see below), it is conceivable that free CydX that is not associated with a cytochrome *bd* oxidase complex might insert into the cytoplasmic membrane and destabilize other cell envelope functions that are essential for resistance to acidic pH and intracellular replication. Our finding that expression of *cydX* in a *cydB* mutant lacking cytochrome *bd* oxidase actually decreased stationary survival (Figure [3A](#F3){ref-type="fig"}) is consistent with this interpretation.

The C terminus of CydX is located in the periplasm
--------------------------------------------------

CydX is predicted to have a single transmembrane domain of 15--17 residues. Since components of cytochrome *bd* oxidase in *E. coli* are located at the cytoplasmic membrane (Miller and Gennis, [@B30]; Green et al., [@B15]; Miller et al., [@B31]) we hypothesized that CydX could mediate its function by colocalizing with CydAB at the cytoplasmic membrane, where it might serve to tether the enzymatic components of the oxidase. To test this hypothesis, we performed membrane fractionation of *B. abortus*, which failed to yield a cytoplasmic membrane fraction of sufficient purity to give conclusive results (data not shown). As a second approach we constructed N- and C-terminal fusions of CydX to TEM-1 β-lactamase (Zhang et al., [@B42]) to determine the topology of CydX in the cytoplasmic membrane. To this end, we designed two constructs by cloning *cydX* in front or behind TEM-1 β-lactamase (Datta and Kontomichalou, [@B5]) with a 3×FLAG epitope replacing the TEM-1 signal sequence. Both constructs of pCydX/FT (FT stands for 3×FLAG::TEM1) and pFT/CydX were DNA sequenced to ensure in-frame expression of Cyd::FT or FT::CydX fusions. Since β-lactamase only confers resistance to β-lactam antibiotics if it localizes to the periplasm, we could conclude based on ampicillin resistance of each recombinant strain whether the TEM-1 domain was localized in the periplasm. As a control for a resident cytosolic protein we constructed a Glutathione S-transferase (GST) β-lactamase fusions. The GST constructs and pFlagTEM1, which is the empty vector to make CydX β-lactamase fusions, were used as negative controls. As a positive control we used pBBR1MCS4, which encodes β-lactam resistance. Expression of CydX::FT allowed *Brucella* to survive a concentration of up to 250 μg/ml, of carbenicillin, a maximal concentration similar to that of positive control pBBR1MCS4, whereas the other strains tested were sensitive to 20 μg/ml of carbenicillin (Figure [4A](#F4){ref-type="fig"}). This result indicated that the β-lactamase moiety of CydX::FT was located in the periplasm, while in FT::CydX, TEM-1 was retained in the cytoplasm. To exclude the possibility that the carbenicillin sensitivity was due to low or absent expression of β-lactamase fusions in those strains, we performed immunoblot analysis of bacterial lysates using a monoclonal antibody specific to TEM-1 β-lactamase (QED Bioscience Inc.). High levels of β-lactamase fusion protein expression were detected in all but the pBBR1MCS4 transformed *Brucella*, which could be attributed to the lower expression from a normal promoter, compared to the IPTG inducible trc promoter in the other constructs, since the TEM-1 constructs share identical sequences to the *bla* gene in pBBR1MCS4 (Figure [4A](#F4){ref-type="fig"}). Based on our current understanding about cytochrome *bd* oxidase in other organisms we predict that *Brucella* CydX is inserted in cytoplasmic membrane, with its N terminus at the cytosolic face and C terminus in the periplasm, as depicted in Figure [4B](#F4){ref-type="fig"}.

![**The C-terminus of CydX is located in the periplasm of *B. abortus*. (A)** Western Blot showing expression levels of β-lactamase fusions to CydX and Glutathione-S-transferase (GST; a cytoplasmic control). Blots were probed with a monoclonal antibody against TEM-1 β-lactamase (right blot). As a loading control, the *B. abortus* protein Bcsp31 detected using a polyclonal antibody (shown on the left) \[Sun et al. ([@B37])\]. **(B)** Maximum concentration of carbenicillin allowing growth of *B. abortus* expressing each β-lactamase fusion protein. Plasmid pBBR1mcs4 is a positive control that expresses β-lactamase resistance. pFlagTEM1 is the plasmid carrying TEM-1 β-lactamase lacking its N-terminal sequence and was used for generating N- and C-terminal fusions to CydX and GST. **(C)** Proposed topological model for CydX in *Brucella* based on current understanding of cytochrome *bd* quinol oxidase in *E. coli* and predicted single transmembrane domain (shaded area) in CydX protein sequence.](fcimb-02-00047-g0004){#F4}

In conclusion, we have identified a small protein, CydX (BAB2_0726) that is co-regulated with CydAB, and is required for full function of cytochrome *bd* oxidase in *B. abortus*. This terminal oxidase is used by *Brucella* spp. to survive inside eukaryotic cells, where it contributes to intracellular replication (Endley et al., [@B10]; Loisel-Meyer et al., [@B29]; Wu et al., [@B41]). Interestingly, in contrast to *B. abortus*, in which *cydB* mutants were highly attenuated, *B. suis cydB* mutants were hypervirulent, suggesting different use of terminal oxidases in these two species (Jimenez de Bagues et al., [@B20]). Additional evidence for CydX expression during *in vitro* growth of *B. abortus* was recently provided by a proteomic study (Lamontagne et al., [@B25]). The requirement of CydX for cytochrome *bd* oxidase function may be shared with other bacteria expressing cytochrome *bd* oxidase, such as *E. coli* and *S. Typhimurium*, since a small protein YbgT was identified downstream of the *cydB* gene in these two organisms (Alix and Blanc-Potard, [@B2]; Hemm et al., [@B18]). In *E. coli*, cytochrome *bd*-I oxidase was shown to assemble into large respiratory domains in the cytoplasmic membrane (Lenn et al., [@B26]), so the insertion of CydX into the cytoplasmic membrane suggests that it might play a role in organizing these complexes at the cytosolic face of the cytoplasmic membrane or might be required for their terminal oxidase activity. Further experimentation will be needed to determine the precise mechanism by which CydX contributes to cytochrome *bd* oxidase function.
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![**Strategy for Allelic Exchange Mutagenesis.** See Materials and Methods for explanation.](fcimb-02-00047-a0001){#FA1}

###### 

**Primers used in this work**.

  **Primer**         **Sequence[^\*^](#TN6){ref-type="table-fn"}**      **Description**
  ------------------ -------------------------------------------------- -----------------------
  GBRORF0459 DN-F    TCC[CCCGGG]{.ul}AAAATAATTGACCATGGCΔ                ΔBAB1_0061
  GBRORF0459 DN-R    AA[CTGCAG]{.ul}GGGCAGGCCCGCCGCCT                   
  GBRORF0459 UP-F    GTGCACCGCATTTATTGCGT                               
  GBRORF0459 UP-R    TCC[CCCGGG]{.ul}TTGCAGATCAAAGAGCG                  
  GBRORF0206 DN-F    TCC[CCCGGG]{.ul}AGCCTGCGTTATGCTGCCCGG              ΔBAB1_0355
  GBRORF0206 DN-R    AAA[CTGCAG]{.ul}CACCACGAAAATGGCCGTG                
  GBRORF0206 UP-F    GCAGGCGCTCAAAATAATGTG                              
  GBRORF0206 UP-R    TCC[CCCGGG]{.ul}CTTTGCGGGGGGCGTTCA                 
  GBRORF0049 DN-F    TCC[CCCGGG]{.ul}ATAGGTGTGCGCCCCGC                  ΔBAB1_0513
  GBRORF0049 DN-R    AA[CTGCAG]{.ul}AAGTCGAATCCGCCCTC                   
  GBRORF0049 UP-F    CCGGCCTTCATGAGCCGGAT                               
  GBRORF0049 UP-R    TCC[CCCGGG]{.ul}TCGTTTTGCGGGCCAAC                  
  GBRORF2128 DN-F    TCC[CCCGGG]{.ul}CCGTTGTTATAAACGACGAC               ΔBAB1_0581
  GBRORF2128 DN-R    AAA[CTGCAG]{.ul}AGCTTTTACCAAAGAACAGG               
  GBRORF2128 UP-F    GGCTCATACCCGCCAAATGCA                              
  GBRORF2128 UP-R    TCC[CCCGGG]{.ul}TTCAGCCGTTCCAGCACTT                
  GBRORF2083 DN-F    TCC[CCCGGG]{.ul}AGAAGAAACTGTTGTT                   ΔBAB1_0626
  GBRORF2083 DN-R    AAA[CTGCAG]{.ul}GTCCTTGTCGTCTTCAACA                
  GBRORF2083 UP-F    CTGCTCAGATCGCCGGATGGC                              
  GBRORF2083 UP-R    TCC[CCCGGG]{.ul}ATTTATTGGCTGTCATATTGTT             
  GBRORF1960 DN-F    TCC[CCCGGG]{.ul}ACGACCTGCTTTCGCAGAT                ΔBAB1_0743
  GBRORF1960 DN-R    AAA[CTGCAG]{.ul}CCCGTATGTAACAATGAG                 
  GBRORF1960 UP-F    CCTATGCAGCTTCCACCATTG                              
  GBRORF1960 UP-R    TCC[CCCGGG]{.ul}TAAGTTTGTGTGCTCATTC                
  GBRORF1747 DN-F    TCC[CCCGGG]{.ul}CTATCCCGCGACGAGCG                  ΔBAB1_0960
  GBRORF1747 DN-R    AAA[CTGCAG]{.ul}AAGCTGATCTTCATCGAT                 
  GBRORF1747 UP-F    GATAGTGCCAGGATAAGGAAA                              
  GBRORF1747 UP-R    TCC[CCCGGG]{.ul}ATGGAAAACTTCATCATT                 
  GBRORF1716 DN-F    TCC[CCCGGG]{.ul}TCAAGAAATTCAACCTT                  ΔBAB1_0992
  GBRORF1716 DN-R    AA[CTGCAG]{.ul}ATCGCCTGATGGCAATC                   
  GBRORF1716 UP-F    TCCGATTGGGCGTAGCTTAC                               
  GBRORF1716 UP-R    TCC[CCCGGG]{.ul}TACTGGCGCTGGCGTCT                  
  GBRORF1608 DN-F    TCC[CCCGGG]{.ul}ACGCTCATCACCTTGACGGA               ΔBAB1_1106
  GBRORF1608 DN-R    AAA[CTGCAG]{.ul}CCCTCCCGCCCCTCACGT                 
  GBRORF1608 UP-F    GGCGAGAGGGATGAAGATCGA                              
  GBRORF1608 UP-R    TCC[CCCGGG]{.ul}TCCATGAAGTTGAAGATTT                
  GBRORF1520 DN-F    TCC[CCCGGG]{.ul}CGATTCCATTAAAACAG                  ΔBAB1_1194
  GBRORF1520 DN-R    AA[CTGCAG]{.ul}AATCATGGCTCTAAATC                   
  GBRORF1520 UP-F    CCTTGGCATGGCGCTGCGTC                               
  GBRORF1520 UP-R    TCC[CCCGGG]{.ul}CCTGTCCTTCGCTCGGG                  
  GBRORF1512 DN-F    TCC[CCCGGG]{.ul}CGTTGCCGTCGGCCATAG                 ΔBAB1_1204
  GBRORF1512 DN-R    AA[CTGCAG]{.ul}CCTGCGGTCCATTCGTA                   
  GBRORF1512 UP-F    GTTGTGCTACTTCATTTACG                               
  GBRORF1512 UP-R    TCC[CCCGGG]{.ul}TCGCCGCACCGCCTG                    
  GBRORF1452 DN-F    TCC[CCCGGG]{.ul}CGACGACGAAGAGGAAGAG                ΔBAB1_1262
  GBRORF1452 DN-R    AAA[CTGCAG]{.ul}ACGCCTTCGTTCATCT                   
  GBRORF1452 UP-F    CAGTGCAGGAACCTTATTGCG                              
  GBRORF1452 UP-R    TCC[CCCGGG]{.ul}ACTCGGATGTGCTTCAATAGC              
  GBRORF1325 DN-F    TCC[CCCGGG]{.ul}TTTGCCGCATGGCTCGACGC               ΔBAB1_1390
  GBRORF1325 DN-R    AAA[CTGCAG]{.ul}CGACGGAGTGGCGGCTCT                 
  GBRORF1325 UP-F    GGCCAGATAGCCCGGAACGA                               
  GBRORF1325 UP-R    TCC[CCCGGG]{.ul}ACCCACATAACATCTAAAGGA              
  GBRORF1323 DN-F    TCC[CCCGGG]{.ul}CATCAGGCGGAGTGACC                  ΔBAB1_1392
  GBRORF1323 DN-R    AAA[CTGCAG]{.ul}GACGTCGGCCTCCATTCTC                
  GBRORF1323 UP-F    GCTTGTGACGCTGGAGGAAAA                              
  GBRORF1323 UP-R    TCC[CCCGGG]{.ul}TCCGACATTTCCGTTATCAAC              
  GBRORF0969 DN-F    AC[CCCGGG]{.ul}CTTTCACCTGCACGAAG                   ΔBAB1_1743
  GBRORF0969 DN-R    AC[CTGCAG]{.ul}ACCTATGGCGTGGATTCG                  
  GBRORF0969 UP-F    ACGCGCGATGGCTCAATGC                                
  GBRORF0969 UP-R    AC[CCCGGG]{.ul}CAGGATTTTGGTCAC                     
  GBRORF0964 DN-F    TCC[CCCGGG]{.ul}TATCCCCATCGAGCTTGCC                ΔBAB1_1748
  GBRORF0964 DN-R    AAA[CTGCAG]{.ul}GATCGCCCGAATGCGATT                 
  GBRORF0964 UP-F    CCGACACCCAGATTCATGCGC                              
  GBRORF0964 UP-R    TCC[CCCGGG]{.ul}TTCTTGAAAACGTCTTTCATG              
  GBRORF0765 DN-F    TCC[CCCGGG]{.ul}TTGATGTCCTTCAATTC                  ΔBAB1_1939
  GBRORF0765 DN-R    AA[CTGCAG]{.ul}GATGCGCCAGACGAA                     
  GBRORF0765 UP-F    ACGGCGCATGCTTCTTGTCG                               
  GBRORF0765 UP-R    TCC[CCCGGG]{.ul}GGGCTGGTTCGGACAAT                  
  GBRORF0663 DN-F    TCC[CCCGGG]{.ul}CAATACGTTCCGGCGAAG                 ΔBAB1_2041
  GBRORF0663 DN-R    AA[CTGCAG]{.ul}GTGTCGAGAAGCTCAAG                   
  GBRORF0663 UP-F    CCTGCATCTGCAAAGGCC                                 
  GBRORF0663 UP-R    TCC[CCCGGG]{.ul}TGGTTGATGCCATCATT                  
  GBRORFA0247 DN-F   TCC[CCCGGG]{.ul}TGTGCGCGGCCAAGATAA                 ΔBAB2_0160
  GBRORFA0247 DN-R   AAA[CTGCAG]{.ul}CCCTGCAAAATTTCCTGT                 
  GBRORFA0247 UP-F   CCATGGGTATGATGATGCTGC                              
  GBRORFA0247 UP-R   TCC[CCCGGG]{.ul}TTTCCCGCAAGCTGCAAGC                
  GBRORFA0258 DN-F   TCC[CCCGGG]{.ul}CGCTTGCCGCCGCCTGATT                ΔBAB2_0170
  GBRORFA0258 DN-R   AAA[CTGCAG]{.ul}ATTGGTGAGGGGGCGAAA                 
  GBRORFA0258 UP-F   CCGCTTCGTCGAACAGGCAAC                              
  GBRORFA0258 UP-R   TCC[CCCGGG]{.ul}GCGTATTCGACATTCTAC                 
  GBRORFA1086 DN-F   TCC[CCCGGG]{.ul}CTTTCCATCGCCTGAAACTGT              ΔBAB2_0232
  GBRORFA1086 DN-R   AAA[CTGCAG]{.ul}GGGAAATGTAGGAGGTAG                 
  GBRORFA1086 UP-F   GAAGAAGGCCTTATCTGATCA                              
  GBRORFA1086 UP-R   TCC[CCCGGG]{.ul}CCGCCCCCTCTTCACCATGA               
  GBRORFA0924 DN-F   TCC[CCCGGG]{.ul}TGGAACACTCTCCCTGC                  ΔBAB2_0400
  GBRORFA0924 DN-R   AA[CTGCAG]{.ul}TCCTTTGCTGCCTTTGT                   
  GBRORFA0924 UP-F   GCGTATCAGCCATGCAGGCG                               
  GBRORFA0924 UP-R   TCC[CCCGGG]{.ul}TAAGACGTAGGTTAGGC                  
  GBRORFA0907 DN-F   TCC[CCCGGG]{.ul}CAGCAATGGTTCGACGAAAG               ΔBAB2_0415
  GBRORFA0907 DN-R   AAA[CTGCAG]{.ul}ACAAATGCACCGAGGAT                  
  GBRORFA0907 UP-F   GCGGATCGGCGAGACTTTTCC                              
  GBRORFA0907 UP-R   TCC[CCCGGG]{.ul}CAGTTCCATGACCCGTTCT                
  GBRORFA0873 DN-F   TCC[CCCGGG]{.ul}CGCTTCCCGCCTACTACTGA               ΔBAB2_0450
  GBRORFA0873 DN-R   AAA[CTGCAG]{.ul}CCATAATGTCCGCAAAC                  
  GBRORFA0873 UP-F   GGTTTTGCAGTGGCTTCCAG                               
  GBRORFA0873 UP-R   TCC[CCCGGG]{.ul}GGCAGCAAACTGGACATT                 
  GBRORFA0854 DN-F   TCC[CCCGGG]{.ul}CTTCTCATCCGCAAGCTA                 ΔBAB2_0470
  GBRORFA0854 DN-R   AAA[CTGCAG]{.ul}ATAGCGCGGCTTGTGCAC                 
  GBRORFA0854 UP-F   CATGTTCAAGCGCACGATCCG                              
  GBRORFA0854 UP-R   TCC[CCCGGG]{.ul}ATATGAATTGATTGACATCAC              
  GBRORFA0598 DN-F   TCC[CCCGGG]{.ul}CAACAAGCACCACTGAAATG               ΔBAB2_0726
  GBRORFA0598 DN-R   AAA[CTGCAG]{.ul}ATATGGCCCGGCGCGGCAT                
  GBRORFA0598 UP-F   CGGCGGCTTCGTGCCGGCGC                               
  GBRORFA0598 UP-R   TCC[CCCGGG]{.ul}TTGCTCTCATCCTCGATCA                
  GBRORFA0563 DN-F   TCC[CCCGGG]{.ul}CCTATGCAGAAGCCCTG                  ΔBAB2_0761
  GBRORFA0563 DN-R   AA[CTGCAG]{.ul}AAGAGAATATGGCCGTC                   
  GBRORFA0563 UP-F   CGCTTTTTCCCGGCAGCATG                               
  GBRORFA0563 UP-R   TCC[CCCGGG]{.ul}TTCGGTTTCAGTTTCTC                  
  GBRORFA0429 DN-F   TCC[CCCGGG]{.ul}CTGAAGCAGAACTCAAGAAAGTT            ΔBAB2_0862
  GBRORFA0429 DN-R   AAA[CTGCAG]{.ul}TTTAATGAGATATTTC                   
  GBRORFA0429 UP-F   CAATGCAGGCGCAATTGCAAC                              
  GBRORFA0429 UP-R   TCC[CCCGGG]{.ul}AAGAGAGCCTTAATCATTTCC              
  GBRORFA1199 DN-F   TCC[CCCGGG]{.ul}TTCCCGTTTCTGCGACG                  ΔBAB2_1072
  GBRORFA1199 DN-R   AAA[CTGCAG]{.ul}ATAACGGCATCAGCACCG                 
  GBRORFA1199 UP-F   GGGCACTTCTTCTGCCACGT                               
  GBRORFA1199 UP-R   TCC[CCCGGG]{.ul}ATAGTTTCGGCTTCGAT                  
  GBRORFA0014 DN-F   TCC[CCCGGG]{.ul}ATGAGTCGCAAAAGCGGAG                ΔBAB2_1087
  GBRORFA0014 DN-R   AAA[CTGCAG]{.ul}GGTTGCCGGCGCCTCTG                  
  GBRORFA0014 UP-F   GGCCGCCGTGCTGGCGTTTTG                              
  GBRORFA0014 UP-R   TCC[CCCGGG]{.ul}CGTGTTCCAGCCTGCGTCAT               
  GBRORFA0062 DN-F   TCC[CCCGGG]{.ul}TAGGCTTATCCAGGCTGTA                ΔBAB2_1136
  GBRORFA0062 DN-R   AAA[CTGCAG]{.ul}GCCTATGGTCTCTTCCCGG                
  GBRORFA0062 UP-F   CCGCTTCTCACATCCATTTTC                              
  GBRORFA0062 UP-R   TCC[CCCGGG]{.ul}CGATGCTGTTATCTTCGAT                
  GroEL-P-F          A[GCATGC]{.ul}CGTTCGGGCGATGGAAACAGGCGTG            Promoter P~GroEL~
  GroEL-P-R          A[CATATG]{.ul}GTATAACCCTTGGTGTTATAGACG             
  dTomato-F          A[CATATG]{.ul}GTGAGCAAGGGCGAGGAGGTC                pGroEL/dsRed
  dTomato-R          A[CCCGGGATGCAT]{.ul}TACTTGTACAGCTCGTCCATGCCGTAC    
  A0598-Flag-F       A[CATATG]{.ul}AGAGCAACCACGCTTAC                    pGroEL/CydX
  A0598 -PstI        A[CTGCAG]{.ul}TCAGTGGTGCTTGTTGCCTTC                
  CydB-F-NdeI        A[CATATG]{.ul}ATACTCAGCGATTTGTTGGACTATC            pGroEL/CydB
  CydB-R-PstI        A[CTGCAG]{.ul}TCAGTAAGCGTGGTTGCTCTCATCCTC          
  CydB-F-NdeI        A[CATATG]{.ul}ATACTCAGCGATTTGTTGGACTATC            pGroEL/CydBX
  A0598 -PstI        A[CTGCAG]{.ul}TCAGTGGTGCTTGTTGCCTTC                
  A0598-Flag-F       A[CATATG]{.ul}AGAGCAACCACGCTTAC                    pCydX/FT
  A0598-Flag-R       A[GTCGAC]{.ul}GTGGTGCTTGTTGCCTTC                   
  A0598 -XbaI        A[TCTAGA]{.ul}AGAGCAACCACGCTTACTGATTG              pFT/CydX
  A0598 -PstI        A[CTGCAG]{.ul}TCAGTGGTGCTTGTTGCCTTC                
  Promoter-F         TTAG[GGTACCGTTAAC]{.ul}GCTCCCCGAAAACGGC            Promoter P~BMEII0192~
  Promoter-R         A[GTCGACATATG]{.ul}TGATTTCCGGC                     
  Flag-F             A[CATATG]{.ul}AGCCTA[GTCGAC]{.ul}TACAAAGACCATGAC   pBBR1Flag
  Flag-R             A[GAGCTCCTGCAG]{.ul}TTACTATTTATCGTCGTCATC          
  A0598-Flag-F       A[CATATG]{.ul}AGAGCAACCACGCTTAC                    pCydX/Flag
  A0598 -PstI        A[CTGCAG]{.ul}TCAGTGGTGCTTGTTGCCTTC                

Engineered restriction sites underlined.
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